26.21
0.14 (0.54%)
| Penutupan Terdahulu | 26.07 |
| Jumlah Dagangan | 167,758 |
| Harga / Jualan (P/S) | 57.91 |
| Harga / Buku (P/B) | 3.00 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.82 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.74% |
| Nisbah Semasa (MRQ) | 31.01 |
| Aliran Tunai Operasi (OCF TTM) | -67.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.00 M |
| Pulangan Atas Aset (ROA TTM) | -22.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Rapport Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -0.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | 2.5 |
| Wang Pintar 30% | 1.6 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | 4.0 |
| Persekitaran | ×0.79 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.5% |
| Persetujuan Tonggak | ×0.98 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 4.8 |
| Skor Akhir | 0.24 |
|
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.28% |
| % Dimiliki oleh Institusi | 105.23% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HEALY JAMES | 22.50 | - | 969,480 | 21,813,300 |
| THIRD ROCK VENTURES V, L.P. | 25.05 | - | 1,428,571 | 35,785,704 |
| Jumlah Keseluruhan Kuantiti Bersih | 2,398,051 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 57,599,004 | |||
| Purata Pembelian Keseluruhan ($) | 24.02 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| THIRD ROCK VENTURES V, L.P. | Pengarah | 30 Oct 2026 | Diperolehi (+) | 238,095 | 25.05 | 5,964,280 |
| THIRD ROCK VENTURES V, L.P. | Pengarah | 30 Oct 2026 | Diperolehi (+) | 1,190,476 | 25.05 | 29,821,424 |
| HEALY JAMES | Pengarah | 28 Oct 2026 | Beli (+) | 969,480 | 22.50 | 21,813,300 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |